BioCryst Pharmaceuticals (MEX:BCRX) Other Current Assets: MXN360 Mil (As of Mar. 2026)


MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
56 GF Score
Price MXN182.00
GF Value MXN219.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Other Current Assets?

BioCryst Pharmaceuticals MEX:BCRX -6.67% 56 Other Current Assets is MXN360 Mil as of Mar. 2026. GuruFocus rates MEX:BCRX with a GF Score™ of 56/100 and a GF Value™ of MXN219.13 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BioCryst Pharmaceuticals's other current assets for the quarter that ended in Mar. 2026 was MXN360 Mil.

BioCryst Pharmaceuticals's quarterly other current assets declined from Sep. 2025 (MXN848 Mil) to Dec. 2025 (MXN313 Mil) but then increased from Dec. 2025 (MXN313 Mil) to Mar. 2026 (MXN360Mil).

BioCryst Pharmaceuticals's annual other current assets declined from Dec. 2023 (MXN362 Mil) to Dec. 2024 (MXN291 Mil) increased from Dec. 2024 (MXN291 Mil) to Dec. 2025 (MXN313 Mil).


BioCryst Pharmaceuticals Other Current Assets Related Terms


BioCryst Pharmaceuticals Other Current Assets Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Other Current Assets Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.47 274.07 362.33 291.19 312.99

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 299.06 794.65 848.49 312.99 360.08
MEX:BCRX
56GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of MXN360 Mil mean?
BioCryst Pharmaceuticals (MEX:BCRX) has a Other Current Assets of MXN360 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on BioCryst Pharmaceuticals.
Is BioCryst Pharmaceuticals' Other Current Assets too high?
BioCryst Pharmaceuticals' current Other Current Assets is MXN360 Mil. Overall, BioCryst Pharmaceuticals has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Other Current Assets compare to SUPN and PBH?
BioCryst Pharmaceuticals' Other Current Assets of MXN360 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on BioCryst Pharmaceuticals. BioCryst Pharmaceuticals's current Other Current Assets is MXN360 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (MEX:BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN219.13, compared to a current price of MXN182.00 — trading 16.9% below its estimated fair value. The current Other Current Assets is MXN360 Mil. BioCryst Pharmaceuticals' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For BioCryst Pharmaceuticals (MEX:BCRX), the current Other Current Assets is MXN360 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 16.9% below its estimated GF Value™ of MXN219.13. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • Other Current Assets: MXN360 Mil
  • GF Value™: MXN219.13 vs. price of MXN182.00 (16.9% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
56GF Score

Get the complete analysis for MEX:BCRX

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN219.13
GF Value